Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

被引：81
|
作者：
Batocchi, AP
Rotondi, M
Caggiula, M
Frisullo, G
Odoardi, F
Nociti, V
Carella, C
Tonali, PA
Mirabella, M
机构：
[1] Catholic Univ, Neurol Inst, I-00168 Rome, Italy
[2] Univ Naples, F Magrassi Inst Endocrinol II, Dept Clin & Expt Med, I-80121 Naples, Italy
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2003年 / 139卷 / 1-2期
关键词：
leptin; cytokines; multiple sclerosis; interferon beta;
D O I：
10.1016/S0165-5728(03)00154-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after I year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：150 / 154
页数：5
相关论文
共 50 条
  • [11] INTERFERON-BETA FOR MULTIPLE-SCLEROSIS
    CONNELLY, JF
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (05) : 610 - 616
  • [12] INTERFERON-BETA IN MULTIPLE-SCLEROSIS
    ARNASON, BGW
    NEUROLOGY, 1993, 43 (04) : 641 - 643
  • [13] INTERFERON-BETA AND MULTIPLE-SCLEROSIS
    CLANET, M
    REVUE NEUROLOGIQUE, 1993, 149 (8-9) : 443 - 444
  • [14] Expression of type I interferon receptor in multiple sclerosis patients treated with different interferon-beta molecules
    Fernandez, O
    Oliver, B
    Luque, G
    Fernandez, V
    Leyva, L
    Guerrero, R
    Blanco, E
    Alonso, A
    Leon, A
    Bustamante, R
    Pinto, MJ
    Tamayo, J
    Mayorga, C
    JOURNAL OF NEUROLOGY, 2004, 251 : 89 - 89
  • [15] Recurrent orbital inflammation in a patient with multiple sclerosis treated with interferon-beta
    Spierer, Oriel
    Leibovitch, Igal
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 (08): : 835 - 837
  • [16] SEVERE SEPTAL PANNICULITIS IN A MULTIPLE SCLEROSIS PATIENT TREATED WITH INTERFERON-BETA
    Mazzon, E.
    Guarneri, C.
    Giacoppo, S.
    Rifici, C.
    Tchernev, G.
    Polimeni, G.
    Wollina, U.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 (04) : 669 - 674
  • [17] Predictive markers to interferon-beta therapy in multiple sclerosis patients
    Charbit, H.
    Geyshis, B.
    Karussis, D.
    Petrou, P.
    Smith, Y.
    Vaknin-Dembinsky, A.
    Lavon, I.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S232 - S233
  • [18] Bioavailability of Interferon-beta in patients with multiple sclerosis - fishing for the surrogate
    Kieseier, B. C.
    Hartung, H. -P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (03) : 344 - 345
  • [19] Menstrual disorders in multiple sclerosis patients receiving interferon-beta
    Lotfi, J.
    Zohrevand, P.
    Heshmat, A.
    Sahraian, M.
    Parsi, H.
    Bagheri, M.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S209 - S209
  • [20] Interferon-beta injection site reactions in patients with multiple sclerosis
    Maurelli, Martina
    Bergamaschi, Roberto
    Antonini, Ambra
    Fargnoli, Maria Concetta
    Puma, Elisa
    Mallucci, Giulia
    Totaro, Rocco
    Girolomoni, Giampiero
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (08) : 831 - 834
12345